Show simple item record

dc.contributor.authorHardcastle, Sarah
dc.contributor.authorLegge, E.
dc.contributor.authorLaundy, C.
dc.contributor.authorEgan, Sarah
dc.contributor.authorFrench, R.
dc.contributor.authorWatts, G.
dc.contributor.authorHagger, Martin
dc.date.accessioned2017-01-30T12:04:46Z
dc.date.available2017-01-30T12:04:46Z
dc.date.created2015-07-31T06:51:31Z
dc.date.issued2015
dc.identifier.citationHardcastle, S. and Legge, E. and Laundy, C. and Egan, S. and French, R. and Watts, G. and Hagger, M. 2015. Patients’ Perceptions and Experiences of Familial Hypercholesterolemia, Cascade Genetic Screening and Treatment. International Journal of Behavioral Medicine. 22 (1): pp. 92-100.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/17904
dc.identifier.doi10.1007/s12529-014-9402-x
dc.description.abstract

Background: Familial hypercholesterolemia (FH) is a serious genetic disorder affecting approximately 1 in every 300 to 500 individuals and is characterised by excessively high low-density lipoprotein (LDL) cholesterol levels, substantially increased risk of early-onset coronary heart disease (CHD) and premature mortality. If FH is untreated, it leads to a greater than 50 % risk of CHD in men by the age of 50 and at least 30 % in women by the age of 60. FH can be diagnosed through genetic screening and effectively managed through pharmacological treatment and lifestyle changes. Purpose: Familial hypercholesterolemia (FH) is a genetic health condition that increases the risk of cardiovascular disease. Although FH can be effectively managed with appropriate pharmacological and dietary interventions, FH detection rate through genetic screening remains low. The present study explored perceptions and experiences of FH patients (N = 18) involved in a genetic cascade screening programme. Methods: Face-to-face interviews were conducted to assess patients’ knowledge and understanding of FH, explore factors linked to adherence to health-protective behaviours and examine perceptions of genetic screening. Results: Thematic analysis of interviews revealed four themes: disease knowledge, severity of FH, lifestyle behavioural change and barriers to cascade screening and treatment. Participants recognised FH as a permanent, genetic condition that increased their risk of CHD and premature mortality. Many participants dismissed the seriousness of FH and the importance of lifestyle changes because they perceived it to be effectively managed through medication. Despite positive attitudes toward screening, many participants reported that relatives were reluctant to attend screening due to their relatives’ ‘fatalistic’ outlook or low motivation. Participants believed that they had insufficient authority or control to persuade family members to attend screening and welcomed greater hospital assistance for contact with relatives. Conclusions: Findings support the adoption of direct methods of recruitment to cascade screening led by medical professionals, who were perceived as having greater authority. Other implications included the need for clinicians to provide clear information, particularly to those who are asymptomatic, related to the seriousness of FH and the necessity for adherence to medication and lifestyle changes.

dc.publisherSpringer New York LLC
dc.subjectDisease knowledge
dc.subjectAttitudes
dc.subjectFamilial hypercholesterolemia
dc.subjectCascade screening
dc.subjectQualitative interviews
dc.titlePatients’ Perceptions and Experiences of Familial Hypercholesterolemia, Cascade Genetic Screening and Treatment
dc.typeJournal Article
dcterms.source.volume22
dcterms.source.number1
dcterms.source.startPage92
dcterms.source.endPage100
dcterms.source.issn1070-5503
dcterms.source.titleInternational Journal of Behavioral Medicine
curtin.note

The final publication is available at Springer via http://doi.org/10.1007/s12529-014-9402-x

curtin.accessStatusOpen access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record